Clinical Trials Logo

Clinical Trial Summary

This is a single center study in which Naglazyme® will be given weekly for two years in patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who have previously been treated with an allogeneic transplant.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02156674
Study type Interventional
Source Masonic Cancer Center, University of Minnesota
Contact
Status Terminated
Phase N/A
Start date January 26, 2016
Completion date December 1, 2019

See also
  Status Clinical Trial Phase
Completed NCT00299000 - A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI Phase 4
Terminated NCT00668564 - Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism Phase 2
Completed NCT01043640 - Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Phase 2